Public company intelligence preview
REPLIMUNE GROUP INC
41 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: $2.8M average total compensation across covered insiders.
Governance movement
Public aggregate: 0 governance events in the last year.
Institutional ownership
Public aggregate: 170 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
Replimune Group Inc is a clinical-stage biotechnology company in the Healthcare sector and Biotechnology industry, focused on developing oncolytic immunotherapies through its proprietary RPx platform. Its lead program, RP1, is being advanced for advanced melanoma and other cancers, with a BLA resubmitted after a prior FDA complete response letter and a new PDUFA date of April 10, 2026. The company also continues work on RP2 in metastatic uveal melanoma, HCC, and BTC, while RP3 is not actively being pursued. Replimune’s operations are centered on clinical trial execution, regulatory filings, and biologics manufacturing, with a sizable U.S. facility and collaborations with Bristol Myers Squibb and Roche supporting development.
Executive Compensation Practices
As a pre-revenue biotech, executive compensation at Replimune is likely driven more by milestone-based incentives than by sales or earnings growth, since the company is still focused on clinical and regulatory execution. Common pay metrics in this type of company include progress on BLA review, trial enrollment and readouts, manufacturing readiness, cash runway management, and successful launch preparation for RP1. The filing summaries suggest compensation committees would probably place significant weight on stock-based awards, since the company is spending heavily on R&D and commercialization planning while still reporting substantial losses. Given the recent FDA setback and resubmission, executive pay outcomes may be especially sensitive to regulatory milestones and the ability to preserve liquidity without excessive dilution.
Insider Trading Considerations
Insider trading patterns in a Biotechnology company like Replimune are often closely tied to binary events such as FDA decisions, clinical data releases, and trial enrollment updates. Because the company’s value is highly dependent on RP1 approval and ongoing RP2 development, insiders may be more cautious about trading around the PDUFA date, FDA interactions, and confirmatory study milestones. The recent complete response letter and resubmitted BLA make this a particularly event-driven name, so insider purchases or sales may be interpreted as signals about confidence in regulatory outcomes or financing needs. Investors should also watch for trades around capital raises, since the company has relied on equity financing and still may need additional funds if RP1 approval or commercialization is delayed.
Unlock the full REPL insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.